Evidence map›Paper›PMID 34744292›Full record

ArticleChemicke zvesti2022

Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations.

Cemal Parlak, Özgür Alver, Cecil Naphtaly Moro Ouma, Lydia Rhyman, Ponnadurai Ramasami

Open access · bronzeAbstract read
In one paragraph

Article in Chemicke zvesti, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Cemal ParlakDepartment of Physics, Science Faculty, Ege University, Izmir, 35100 Turkey.
Özgür AlverDepartment of Physics, Science Faculty, Eskisehir Technical University, Eskisehir, Turkey.
Cecil Naphtaly Moro OumaHySA-Infrastructure CoC, Faculty of Engineering, North-West University, Private Bag X6001, Potchefstroom, 2531 South Africa.
Lydia RhymanComputational Chemistry Group, Department of Chemistry, Faculty of Science, University of Mauritius, Réduit, 80837 Mauritius.
Ponnadurai RamasamiComputational Chemistry Group, Department of Chemistry, Faculty of Science, University of Mauritius, Réduit, 80837 Mauritius.
Ege University · TREskisehir Technical University · TRNorth-West University · ZAUniversity of Johannesburg · ZAUniversity of Mauritius · MU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxychloroquine (HCQ) and favipiravir (FPV) are known to be effective antivirals, and there are reports about their use to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) despite that these are not conclusive. The use of combined drugs is common in drug discovery, and thus, we investigated HCQ and FPV as a combined drug. The density functional theory method was used for the optimization of geometries, spectroscopic analysis and calculation of reactivity parameters. The quantum theory of atoms in molecules was applied to explain the nature of the hydrogen bonds and confirm the higher stability of the combined drug. We also evaluated the absorption, distribution, metabolism and excretion (ADME) parameters to assess their drug actions jointly using SwissADME. The preliminary findings of our theoretical study are promising for further investigations of more potent and selective antiviral drugs. Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s11696-021-01946-8.

Indexed as

ADMEDFTDrug interactionsFavipiravirHydroxychloroquineQTAIM

Identifiers

PMID34744292
PMCPMC8562770
OpenAlexW3210013718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.